Free Trial

Los Angeles Capital Management LLC Has $282.71 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences logo with Medical background

Los Angeles Capital Management LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 422.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,523,036 shares of the biopharmaceutical company's stock after purchasing an additional 2,040,261 shares during the period. Gilead Sciences makes up approximately 1.2% of Los Angeles Capital Management LLC's holdings, making the stock its 14th biggest position. Los Angeles Capital Management LLC owned 0.20% of Gilead Sciences worth $282,706,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences in the first quarter worth about $25,000. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Core Alternative Capital grew its holdings in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the period. Annis Gardner Whiting Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares during the period. Finally, Investment Research & Advisory Group Inc. boosted its holdings in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on GILD shares. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $111.38.

View Our Latest Research Report on Gilead Sciences

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the completion of the sale, the chief financial officer directly owned 162,610 shares in the company, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $333,090.00. Following the sale, the insider owned 117,168 shares in the company, valued at approximately $13,009,163.04. This trade represents a 2.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,000 shares of company stock worth $7,844,775 in the last quarter. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Trading Down 0.5%

GILD stock traded down $0.58 during midday trading on Friday, hitting $108.22. 6,627,889 shares of the company's stock were exchanged, compared to its average volume of 7,673,118. The business has a 50-day simple moving average of $108.81 and a two-hundred day simple moving average of $105.26. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $134.62 billion, a PE ratio of 22.78, a P/E/G ratio of 0.70 and a beta of 0.29. Gilead Sciences, Inc. has a 1-year low of $70.78 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the business posted ($1.32) earnings per share. The company's quarterly revenue was down .3% on a year-over-year basis. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date was Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines